Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on April 3, 2019, covering the event date of March 29, 2019. The filing addresses a change in the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance events and does not contain financial statements.
Material Changes
On March 29, 2019, Joel S. Marcus resigned from the Company's Board of Directors effective immediately. The Company stated that Mr. Marcus's resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the specific event of the director's departure.
Key Facts for Investor Verification
- Joel S. Marcus resigned from the Board of Directors effective March 29, 2019.
- The resignation was voluntary and not due to any disagreement with the Company.
- No financial data or operational updates were included in this specific filing.